Literature DB >> 14564185

Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease.

Antonio Tursi1, Giovanni Brandimarte, Gian Marco Giorgetti.   

Abstract

Gluten-free diet (GFD) plays a key role in the treatment of celiac disease (CD), but it is difficult to evaluate the effect of GFD on the improvement of villous architecture using sensitive, non-invasive tests. Aim of this study is to evaluate anti-transglutaminase (tTG) antibodies in the follow-up of CD to detect histologic recovery. We studied 42 consecutive patients with CD. In all the patients anti-tTG antibodies (evaluated by the enzyme linked immunosorbent assay method) and EGDscopy with multiple bioptic samples before GFD and then 6, 12, and 18 months after GFD were evaluated. For comparison, a sorbitol H2-breath test (H2-BT) and anti-endomysium (EMA) antibodies test were carried out concomitantly. Anti-tTG results were positive in 36 of 42 patients before GFD (80.95%), while they were positive in 11 of 34 (32.35%), 1 of 17 (5.88%), and 0 of 6 (0%) of patients with a persistence in histologic lesions 6, 12, and 18 months of GFD respectively, without any correlation with persistence of histologic lesions (P = NS). Also EMA failed to show correlation with improvement of histologic lesions. They were positive in 31 of 42 patients before GFD (73.80%), while they were positive in 18 of 34 (52.94%), 3 of 17 (17.64%), and 0 of 6 (0%) cases 6, 12, and 18 months of GFD respectively (P = NS). Regarding sorbitol H2-BT, it was positive in 40 of 42 (95.24%) patients before GFD, while it was positive in 31 of 34 (91.17%), 13 of 17 (76.47%), and 4 of 6 (50%) of patients with a persistence in histologic lesions 6, 12, and then 18 months after GFD starting (see Fig. 2, infra). So, anti-tTG and EMA were ineffective in assessing the histologic recovery at each follow-up visit (P = NS), while sorbitol H2-BT seems more effective than anti-tTG and EMA in this field (P < 0.0001 sorbitol H2-BT versus anti-tTG and versus EMA at 18 months after gluten withdrawal). Thirty-eight of 42 (90.47%) patients adhered to a strict GFD. Four patients were found to have occasional dietary transgression, and in all we noted a progressive decreasing of anti-tTG after 6 months of GFD and negative anti-tTG after 12 months of GFD, but sorbitol H2-BT persisted being positive during the entire follow-up. Intestinal damage persisted during the follow-up, despite anti-tTG and EMA negativity, and worsened in the presence of dietary lapses. Anti-tTG does not seem effective to assess histologic recovery in the follow-up of celiac patients after they have started GFD due to its poor correlation with histologic damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564185     DOI: 10.1097/00004836-200311000-00007

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  27 in total

1.  Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease.

Authors:  Shadi Rashtak; Michael W Ettore; Henry A Homburger; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03-04       Impact factor: 11.382

Review 2.  Pearls and pitfalls in the diagnosis of adult celiac disease.

Authors:  H J Freeman
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

3.  Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease.

Authors:  B N Spatola; K Kaukinen; P Collin; M Mäki; M F Kagnoff; P S Daugherty
Journal:  Aliment Pharmacol Ther       Date:  2014-01-06       Impact factor: 8.171

4.  Enteropathy associated T cell lymphoma: common in coeliac disease.

Authors:  Gabrielle Christina Colleran; Kevin Christopher Cronin; Mary Casey; Fadel Bennani; Iqdam Tobbia; Kevin Barry
Journal:  BMJ Case Rep       Date:  2009-02-23

5.  25-year-old woman with anemia.

Authors:  Ranjini R Roy; Matthew R Thomas
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

6.  Intestinal titres of anti-tissue transglutaminase 2 antibodies correlate positively with mucosal damage degree and inversely with gluten-free diet duration in coeliac disease.

Authors:  A Tosco; R Auricchio; R Aitoro; D Ponticelli; M Primario; E Miele; V Rotondi Aufiero; V Discepolo; L Greco; R Troncone; M Maglio
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 7.  Immunogenetic Pathogenesis of Celiac Disease and Non-celiac Gluten Sensitivity.

Authors:  Celia Escudero-Hernández; Amado Salvador Peña; David Bernardo
Journal:  Curr Gastroenterol Rep       Date:  2016-07

Review 8.  Serum markers in the clinical management of celiac disease.

Authors:  Marlou Adriaanse; Daniel A Leffler
Journal:  Dig Dis       Date:  2015-04-22       Impact factor: 2.404

Review 9.  The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis.

Authors:  Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

Review 10.  Long-term follow-up of individuals with celiac disease: an evaluation of current practice guidelines.

Authors:  Jocelyn A Silvester; Mohsin Rashid
Journal:  Can J Gastroenterol       Date:  2007-09       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.